Antiviral Treatment in COVID-19 Outpatients: A Systematic Review of Randomized Controlled Trials
Li Q, Guan X, Wu P, et al. Early transmission dynamics in wuhan, china, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199–207. https://doi.org/10.1056/NEJMoa2001316.
WHO. Coronavirus disease (COVID-19) situation reports. Coronavirus Disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed May 15, 2022).
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020:m1091. https://doi.org/10.1136/bmj.m1091.
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. https://doi.org/10.3389/fimmu.2020.01441.
Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody ly-cov555 in outpatients with COVID-19. N Engl J Med. 2021;384:229–37. https://doi.org/10.1056/NEJMoa2029849.
Choi HM, Moon SY, Yang HI, Kim KS. Understanding viral infection mechanisms and patient symptoms for the development of COVID-19 therapeutics. IJMS. 2021;22:1737. https://doi.org/10.3390/ijms22041737.
Chugh H, Awasthi A, Agarwal Y, Gaur RK, Dhawan G, Chandra R. A comprehensive review on potential therapeutics interventions for COVID-19. European Journal of Pharmacology 2021;890:173741. https://doi.org/10.1016/j.ejphar.2020.173741.
Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15:102329. https://doi.org/10.1016/j.dsx.2021.102329.
Hung Y-P, Lee J-C, Chiu C-W, et al. Oral nirmatrelvir/ritonavir therapy for COVID-19: the dawn in the dark? Antibiotics. 2022;11:220. https://doi.org/10.3390/antibiotics11020220.
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–23. https://doi.org/10.1002/jmv.25681.
Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci USA. 2017;114:206–14. https://doi.org/10.1073/pnas.1617020114.
Hessel MHM, Cohen AF, Rissmann R. Sofosbuvir and daclatasvir. Br J Clin Pharmacol. 2016;82:878–9. https://doi.org/10.1111/bcp.13011.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:n71. https://doi.org/10.1136/bmj.n71.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019:l4898. https://doi.org/10.1136/bmj.l4898.
Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clinical Microbiology and Infection. 2022;28:602–8. https://doi.org/10.1016/j.cmi.2021.12.026.
Holubar M, Subramanian A, Purington N, et al. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial. Infectious Diseases. (except HIV/AIDS); 2021. https://doi.org/10.1101/2021.11.22.21266690.
Lowe DM, Brown L-AK, Chowdhury K, et al. Favipiravir, lopinavir-ritonavir or combination therapy (Flare): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. Infectious Diseases (except HIV/AIDS). 2022. https://doi.org/10.1101/2022.02.11.22270775.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–20. https://doi.org/10.1056/NEJMoa2116044.
Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14:eabl7430. https://doi.org/10.1126/scitranslmed.abl7430.
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386:305–15. https://doi.org/10.1056/NEJMoa2116846.
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397–408. https://doi.org/10.1056/NEJMoa2118542.
Reis G, Moreira Silva EA dos S, Medeiros Silva DC, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the together randomized clinical trial. JAMA Netw Open. 2021;4:e216468. https://doi.org/10.1001/jamanetworkopen.2021.6468.
Ramachandran R, Bhosale V, Reddy H, et al. Phase iii, randomized, double-blind, placebo controlled trial of efficacy, safety and tolerability of antiviral drug umifenovir vs standard care of therapy in non-severe COVID-19 patients. International Journal of Infectious Diseases. 2022;115:62–9. https://doi.org/10.1016/j.ijid.2021.11.025.
Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2021;76:753–7. https://doi.org/10.1093/jac/dkaa501.
Ruzhentsova TA, Oseshnyuk RA, Soluyanova TN, et al. Phase 3 trial of coronavir (Favipiravir) in patients with mild to moderate COVID-19. Am J Transl Res. 2021;13:12575–87.
Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. Journal of Antimicrobial Chemotherapy. 2021;76:3286–95. https://doi.org/10.1093/jac/dkab318.
Parienti J-J, Prazuck T, Peyro-Saint-Paul L, et al. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. EClinicalMedicine. 2021;38:100993. https://doi.org/10.1016/j.eclinm.2021.100993.
McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological basis and rationale for early outpatient treatment of sars-cov-2 (COVID-19) infection. The American Journal of Medicine. 2021;134:16–22. https://doi.org/10.1016/j.amjmed.2020.07.003.
Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases. 2021;102:501–8. https://doi.org/10.1016/j.ijid.2020.10.069.
Özlüşen B, Kozan Ş, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40:2575–83. https://doi.org/10.1007/s10096-021-04307-1.
Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21:489. https://doi.org/10.1186/s12879-021-06164-x.
Cannalire R, Cerchia C, Beccari AR, Di Leva FS, Summa V. Targeting sars-cov-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities. J Med Chem. 2022;65:2716–46. https://doi.org/10.1021/acs.jmedchem.0c01140.
Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N Engl J Med. 2021;385:1382–92. https://doi.org/10.1056/NEJMoa2102685.
Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632. https://doi.org/10.1001/jama.2021.0202.
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for COVID-19 with sars-cov-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50. https://doi.org/10.1056/NEJMoa2107934.
Budi DS, Rofananda IF, Pratama NR, et al. Ozone as an adjuvant therapy for COVID-19: A systematic review and meta-analysis. International Immunopharmacology. 2022;110:109014. https://doi.org/10.1016/j.intimp.2022.109014.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.